Autoplaque vs EchoSolv AS

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Autoplaque

by APQ Health (formerly Cedars-Sinai Medical Center: AIM)

EchoSolv AS

by Echo IQ

AI Verdict

Autoplaque specializes in the quantitative analysis of coronary plaques and luminal stenoses from CT angiography images to aid in heart attack risk prediction. EchoSolv AS, on the other hand, focuses on analyzing echocardiogram measurements to identify patients at risk for severe aortic stenosis. While both are FDA-cleared AI tools in cardiology, they address distinct cardiac conditions and utilize different diagnostic imaging modalities.

Choose Autoplaque if…

Choose Autoplaque if your primary need is a detailed, quantitative analysis of coronary artery plaque and luminal stenoses directly from CT angiography images. This workstation-based software is ideal for clinicians seeking to precisely characterize atherosclerotic plaque burden and assess coronary anatomy to inform heart attack risk prediction and guide treatment strategies.

View Autoplaque →

Choose EchoSolv AS if…

Choose EchoSolv AS if your goal is rapid, AI-powered clinical decision support for identifying patients at high risk for severe aortic stenosis from echocardiogram measurements. This cloud-based solution is best suited for optimizing workflow efficiency by providing ultra-fast risk detection and prioritizing studies for closer review in high-volume cardiology settings.

View EchoSolv AS →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Autoplaque	EchoSolv AS
Deployment	Workstation-based post-processing application, runs on Windows or Mac OS.	Cloud-based
BAA Available	Unknown	Yes AI-estimated
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

EchoSolv AS

EchoSolv AS is cloud-based and explicitly designed for seamless integration into existing workflows, including PACS, without requiring EMR integration. Its ultra-fast risk detection (under 3 seconds) and measurement-based AI suggest a streamlined and efficient user experience. Autoplaque, while offering editable segmentation, is workstation-based, which might imply more local setup and maintenance.

Clinical Value

Autoplaque

Autoplaque provides detailed quantitative analysis of coronary plaques and luminal stenoses from CT angiography, directly aiding in heart attack risk prediction and treatment guidance. This granular, objective assessment of coronary artery disease offers profound clinical value for personalized patient management. EchoSolv AS, while valuable for identifying severe aortic stenosis risk, focuses on a more specific diagnostic probability.

Pricing & Value

Tie

Both Autoplaque and EchoSolv AS have undisclosed pricing, making it impossible to conduct a head-to-head comparison on cost-effectiveness or overall value. Without transparent pricing information, a definitive winner cannot be determined for this dimension.

Enterprise Readiness

EchoSolv AS

EchoSolv AS explicitly states it is HIPAA compliant and has a Business Associate Agreement (BAA), which are fundamental requirements for enterprise healthcare deployments. Its cloud-based deployment also offers greater scalability and easier management compared to Autoplaque's workstation-based approach, which lacks specified compliance details.

Innovation

Autoplaque

Autoplaque demonstrates significant innovation through its AI-powered quantitative analysis of coronary plaques and luminal stenoses directly from CT angiography images. Its automated vessel, plaque, and lumen segmentation, which is also reviewable and editable, represents a sophisticated application of AI in complex image analysis for detailed cardiovascular risk assessment. EchoSolv AS's measurement-based AI is efficient but less groundbreaking in its core analytical approach.

Support & Docs

Tie

The provided structured facts and available web search results do not offer specific information regarding the support channels, documentation, or service level agreements for either Autoplaque or EchoSolv AS. Without this crucial information, a comparative assessment of their support and documentation capabilities is not possible.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Autoplaque	EchoSolv AS
Name	Autoplaque	EchoSolv AS
Company	Cedars-Sinai Medical Center: AIM	Echo IQ
Description	Autoplaque, developed by Cedars-Sinai AIM, is an FDA-cleared AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance.	EchoSolv AS is an FDA-cleared, AI-powered clinical decision support platform by Echo IQ that analyzes echocardiograms to identify patients at risk for severe aortic stenosis with high accuracy and efficiency, integrating into existing workflows.
Categories	Cardiology AI, Radiology & Imaging AI	Cardiology AI, Clinical Decision Support & Reference
Specialties	Cardiology, Radiology	Cardiology, Cardiothoracic Surgery
Key Features	AI-powered quantitative analysis of atherosclerotic plaque; Detection and characterization of coronary artery plaque; Measurement of luminal stenoses; Analysis of coronary anatomy and pathology from CT Angiographic images; Workstation-based post-processing application; Automated vessel, plaque, and lumen segmentation (reviewable and editable by clinician); Review of heart and coronary vessels in Multiplanar Reformatting (MPR), curved MPR, and straightened MPR views; Measurement of vessel diameter and area	AI-powered clinical decision support for severe aortic stenosis probability; Consistent severe AS probability and guideline check from measurements; Second reader support to help prioritize studies for closer review; Real-world readiness; AI does not use LVOT measurements; Faster clinical review using standardized, measurement-based AI and guideline analysis; Measurement-based AI (analyzes numerical measurements, not images); Designed to fit existing workflows (no EMR integration required, integrates with PACS); Ultra-fast risk detection (under 3 seconds)

Videos

Demos, reviews, and walkthroughs featuring Autoplaque and EchoSolv AS.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What is the primary clinical application of Autoplaque versus EchoSolv AS?

Autoplaque is designed for AI-powered quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction. EchoSolv AS is an AI-powered clinical decision support platform that analyzes echocardiograms to identify patients at risk for severe aortic stenosis.

Which imaging modalities do these tools utilize for their analysis?

Autoplaque performs analysis on CT angiography images. EchoSolv AS analyzes numerical measurements derived from echocardiograms, rather than the images directly.

What are the key differences in their AI's analytical approach?

Autoplaque uses AI for automated vessel, plaque, and lumen segmentation directly from CT angiographic images, which clinicians can review and edit. EchoSolv AS uses measurement-based AI to analyze numerical data from echocardiograms to provide severe aortic stenosis probability and guideline checks.

What specific features do they offer to support clinical review?

Autoplaque offers automated segmentation that is reviewable and editable by clinicians, along with review of heart and coronary vessels in various Multiplanar Reformatting (MPR) views. EchoSolv AS provides consistent severe AS probability and guideline checks, along with second reader support to help prioritize studies for closer review.